Effects on Social and Cognition Functions of Blonanserin in First Episode Schizophrenia Patients

Inclusion Criteria: * Schizophrenia patients diagnosis either with DSM-5 criteria or ICD-10; * PANSS total score ≥70; * Males or Females aged 18-45 years; * With disease course less than 5 years and during their first episode; * ≥9 years of education; * Without receiving systematic antipsychotic treatment, or receiving continuous antipsychotic treatment for less than 6 weeks and receiving antipsychotic treatment for less than 6 months in total; * Ability to read and understand Chinese; * Provision of written informed consent Exclusion Criteria: * Severe or unstable physical diseases judged by investigators; * Loss of consciousness more than 1 hour due to any reason in the past 1 year; * Current substance misuse (in 3 months) or any substance dependence; * Pregnant or lactating woman; * Patients with attempted suicide history, severe suicidal ideation or behaviour; * Mental retardation; * Contradict to the study drugs; * Patients taken other investigation products in the past 30 days before entry; * Patients ever taken blonanserin before; * Any current medical condition that would interfere with the assessment of efficacy; * Physical symptoms of acute deterioration requiring hospitalization or increased intensive care; * Significant muscle tension or Parkinson's disease; * Clinically significant abnormal laboratory test results (blood, urine, and blood biochemical analysis); * Clinically significant Abnormal electrocardiogram as judged by researchers; * Participants continuously using sedative drugs, or anticholinergic agents within 3 months of the study; * Those who had undergone electroconvulsive therapy within 3 month of the study; * Those who had received long-acting injection treatment within 3 month of the study; * Those who could not swallow medication with water; * Subjects judged by the investigator in charge as inappropriate for the study